Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1146146 | 1.00 | — | — | |
| SCHEMBL8184207 | 1.00 | KDM1A (0.34) | KDM1AALDH1A1HDAC4HDAC2HDAC8 | |
| SCHEMBL789929 | 1.00 | — | — | |
| SCHEMBL23532635 | 1.00 | KDM1A (0.34) | KDM1AALDH1A1HDAC4HDAC2HDAC8 | |
| SCHEMBL4577624 | 1.00 | KDM1A (0.34) | KDM1AALDH1A1HDAC4HDAC2HDAC8 | |
| SCHEMBL23532670 | 1.00 | — | — | |
| SCHEMBL3958 | 0.97 | — | — | |
| SCHEMBL2808 | 0.88 | — | — | |
| Ethylene SCHEMBL28695708 | 0.71 | TYMP (0.38) | KDM1AALDH1A1HDAC4HDAC2HDAC8 | |
| SCHEMBL3233355 | 0.69 | TYMP (0.41) | KDM1AALDH1A1HDAC4HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6140338-A | FOR TREATING ACUTE INFLAMMATORY DISEASES, CHRONIC INFLAMMATORY DISEASES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, CANCER, ISCHEMIC REFLOW DISORDER AND/OR ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2000-10-31 | — | — | US | claimed |
| EP-0916668-A1 | CHEMOKINE RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | claimed |
| US-20230064214-A1 | TREATMENT AND PROGNOSIS OF PANCREATIC CANCER | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2023-03-02 | — | — | US | disclosed |
| CN-115003334-A | Treatment and prognosis of pancreatic cancer | 剑桥企业有限公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021123813-A1 | TREATMENT AND PROGNOSIS OF PANCREATIC CANCER | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2021-06-24 | — | — | WO | disclosed |
| US-7452908-B2 | Amide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-11-18 | — | — | US | disclosed |
| US-6809108-B1 | SELECTIVE MUSCARINIC M3 RECEPTOR ANTAGONTS; REDUCED SIDE EFFECTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-10-26 | — | — | US | disclosed |
| US-20040204369-A1 | Novel amide derivatives | MSD K.K. (JP) | 2004-10-14 | — | — | US | disclosed |
| EP-1213281-B1 | NOVEL AMIDE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-02-18 | — | — | EP | disclosed |
| EP-1213281-A1 | NOVEL AMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-06-12 | — | — | EP | disclosed |
| US-6140338-A | FOR TREATING ACUTE INFLAMMATORY DISEASES, CHRONIC INFLAMMATORY DISEASES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, CANCER, ISCHEMIC REFLOW DISORDER AND/OR ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2000-10-31 | — | — | US | disclosed |
| EP-0916668-A1 | CHEMOKINE RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204369-A1 | Novel amide derivatives | CHRM3, CHRM1, CHRM2 | KDM1A 717/4885ALDH1A1 1744/4885HDAC4 2830/4885 |
| US-20230064214-A1 | TREATMENT AND PROGNOSIS OF PANCREATIC CANCER | PDCD1, CCR1, CD274 | KDM1A 3297/4885ALDH1A1 1292/4885HDAC4 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.